Sugi Predict

Sugi Predict / Compounds / SCHEMBL4355764

SCHEMBL4355764

SCHEMBL4355764

CNc1cccc(-c2nccs2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 1/20 0.55
▸ EGFR P00533 1/20 0.49
▸ ADRB2 P07550 1/20 0.49
▸ CYP2A6 P11509 1/20 0.49
▸ LOXL2 Q9Y4K0 1/20 0.45
▸ SYK P43405 2/20 0.44
▸ SRC P12931 1/20 0.44
▸ CDK2 P24941 1/20 0.44
▸ ZAP70 P43403 1/20 0.44
▸ KAT6A Q92794 1/20 0.42
▸ CYP1A1 P04798 3/20 0.41
▸ CYP1A2 P05177 3/20 0.41
▸ CYP1B1 Q16678 3/20 0.41
▸ CFTR P13569 1/20 0.41
▸ PLK1 P53350 1/20 0.41
▸ CARM1 Q86X55 1/20 0.41
▸ PRMT1 Q99873 1/20 0.41
▸ SMPD3 Q9NY59 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15606528 0.86 PDPK1 (0.58) PDPK1EGFRADRB2CYP2A6LOXL2
SCHEMBL13994026 0.83 PDPK1 (0.50) PDPK1EGFRADRB2CYP2A6LOXL2
SCHEMBL5216527 0.83 EGFR (0.52) PDPK1EGFRADRB2CYP2A6LOXL2
SCHEMBL15805858 0.82 PDPK1 (0.72) PDPK1EGFRADRB2CYP2A6LOXL2
SCHEMBL8078445 0.80 EGFR (0.47) PDPK1EGFRADRB2CYP2A6LOXL2
SCHEMBL2654169 0.80 PDPK1 (0.50) PDPK1EGFRADRB2CYP2A6LOXL2
SCHEMBL30849066 0.79 EGFR (0.55) PDPK1EGFRADRB2CYP2A6LOXL2
SCHEMBL12582187 0.79 ADRB2 (0.64) PDPK1ADRB2CYP2A6LOXL2SYK
SCHEMBL4452723 0.78 PDPK1 (0.53) PDPK1CYP2A6CDK2KAT6ANPC1
SCHEMBL16159287 0.78 PDPK1 (0.67) PDPK1EGFRADRB2CYP2A6LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2024-07-30 — — US disclosed
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2023-04-13 — — US disclosed
EP-4104861-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2022-12-21 — — EP disclosed
CN-108929263-B Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2022-07-22 — — CN disclosed
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2021-09-09 — — US disclosed
WO-2021141041-A1 THERAPEUTIC AGENT FOR TAUOPATHIES 大日本住友製薬株式会社 2021-07-15 — — WO disclosed
EP-3828174-A1 PYRIDAZINONE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2021-06-02 — — EP disclosed
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2021-01-05 — — US disclosed
CN-111108092-A Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2020-05-05 — — CN disclosed
WO-2020017587-A1 PYRIDAZINONE DERIVATIVE 大日本住友製薬株式会社 2020-01-23 — — WO disclosed
CN-108929263-A Aryl amide Kv2.1 inhibitor and preparation method thereof, pharmaceutical composition and purposes 中国医学科学院药物研究所 2018-12-04 — — CN disclosed
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2016-09-08 — — US disclosed
US-9259426-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2016-02-16 — — US disclosed
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 — — US disclosed
WO-2008009078-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR4A1 PDPK1 4464/4885EGFR 2581/4885ADRB2 291/4885
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES MAPT, PSEN1, PSEN2 PDPK1 1298/4885EGFR 4765/4885ADRB2 1757/4885
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR4A1 PDPK1 4464/4885EGFR 2581/4885ADRB2 291/4885
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR5A2, NR4A1 PDPK1 4546/4885EGFR 1831/4885ADRB2 249/4885
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR5A2 PDPK1 4554/4885EGFR 1826/4885ADRB2 230/4885
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR5A2 PDPK1 4554/4885EGFR 1826/4885ADRB2 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.